drug_type
RELEVANT_DRUG
intervention_type
Drug
drug_description
An antibody–drug conjugate (brand name Besponsa) comprising a humanized anti-CD22 IgG4 monoclonal antibody linked to the cytotoxic agent calicheamicin; it binds CD22 on B-lymphoblasts, is internalized, and releases calicheamicin intracellularly to induce DNA double-strand breaks and apoptosis.
nci_thesaurus_concept_id
C71542
nci_thesaurus_preferred_term
Inotuzumab Ozogamicin
nci_thesaurus_definition
A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody covalently linked to N-acetyl-gamma-calicheamicin dimethyl hydrazide (CalichDMH) with potential antineoplastic activity. Inotuzumab ozogamicin is rapidly internalized upon binding of the antibody moiety to B cell-specific CD22 receptors, delivering the conjugated CalichDMH intracellularly; the CalichDMH moiety binds to the minor groove of DNA in a sequence-specific manner, resulting in double-strand DNA breaks and apoptosis. CalichDMH is a derivative of gamma calicheamicin, a cytotoxic antibiotic produced by the bacterium Micromonospora echinospora.
drug_mesh_term
Inotuzumab Ozogamicin
drug_category
ANTIBODY DRUG CONJUGATE
drug_class
Conjugate
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized anti-CD22 IgG4 antibody-drug conjugate; after binding CD22 on B cells and being internalized, it releases the cytotoxic payload calicheamicin, which binds the DNA minor groove and causes double-strand breaks, leading to apoptosis.
drug_name
inotuzumab ozogamicin
nct_id_drug_ref
NCT05687032